abstract |
<B> USE OF IL-1BETA COMPOUNDS <D>. The present invention relates to a novel use of IL-1β ligand / IL-1Î ± receptor receptor disrupting compounds (referred to herein as "IL-1 beta compounds"); such as small molecular weight compounds that disrupt IL-1 <225> linker / IL-1 <225> receptor interaction, IL-1 <225> antibodies or IL-1 <225> receptor antibodies, such as for example, IL-1β binding molecules described herein, for example the antibodies described herein, for example IL-1β binding compounds or IL-1β receptor binding compounds. >, and / or RNA compounds which decrease both the levels of lL-1 <225> ligands and lL-1 <225> receptor protein for the treatment and / or prevention of autoinflammatory syndromes, such as juvenile rheumatoid arthritis syndromes or rheumatoid arthritis in adults and methods for the treatment and / or prevention of autoinflammatory syndromes such as juvenile rheumatoid arthritis syndromes or adult rheumatoid arthritis in mammals , specifically humans. |